Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
hVIVO secures biggest field study contract to date
(Sharecast News) - Specialist contract research organisation hVIVO announced its engagement in a phase 2b field study for an influenza drug candidate on Tuesday. The AIM-traded firm said the significant contract with a US company would involve enrolling up to 1,000 healthy volunteers, with hVIVO serving as the sole UK clinical site.
It described the study as a randomised, double-blind, placebo-controlled, multicentre dose selection trial.
hVIVO would recruit participants through its dedicated volunteer recruitment platform, FluCamp.
Volunteers would receive either the influenza drug candidate or a placebo at hVIVO's Plumbers Row site, and would be monitored over subsequent months with regular clinical check-ups to evaluate the drug's efficacy and safety.
The study was set to start in the fourth quarter of 2024, with the majority of the contract revenue expected to be recognized in the 2025 financial year.
hVIVO said the engagement was its largest field study contract to date, introducing a new income stream that was expected to enhance staff use and leverage its in-house volunteer recruitment capabilities.
Additionally, as part of its strategic move to Canary Wharf, hVIVO said it was expanding its Plumbers Row outpatient unit.
The expansion would increase the facility's capacity to support future phase two and three field study contracts, aligning with the company's goal to diversify its revenue streams.
"I am delighted to sign this field study contract to assess the efficacy and safety of our client's influenza drug candidate," said chief executive officer Yamin 'Mo' Khan.
"This is our largest field study contract to date, further evidencing the recognition we have earned for our highly effective recruitment capabilities and also opens up a new growth opportunity for the group."
Khan said the project came at a time when the company was expanding its screening site in London to accommodate such studies.
"Our achievements in recruiting large numbers of volunteers and patients into clinical studies was a key reason for this award.
"This is an important facet of our growth strategy that will diversify our revenue base whilst using our existing resources and infrastructure."
At 1202 BST, shares in hVIVO were up 2.41% at 27.6p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.
